Pharmacy stakeholders’ perceptions of opioid use disorder vaccines

Editor’s Note: Amanda Pratt’s first contribution to our Pharmaceutical Inequalities series offers this insightful interview with Vincent Wartenweiler PharmD, an independent community pharmacist and Master’s student in Psychoactive Pharmaceutical Investigation at UW-Madison. Amanda (AP) and Vincent (VW) sat down on March 24, 2022 to discuss a qualitative project Vincent published in 2021 to determine perceptions of pharmacy stakeholders around opioid use disorder vaccines. In addition to providing a glimpse into a significant milestone for the history of alcohol, drugs and pharmacy–the development of substance use disorder vaccines–this interview sheds light on potential methodologies for understanding vaccine hesitancy. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

Sex, Vaccines, and Drug Prescriptions

Editor’s Note: This post by Ejura Salihu is the third in our Pharmaceutical Inequalities series. Ejura’s experience of a disrupted menstrual cycle post-COVID19 vaccination prompted her to write a much-needed commentary on why medical trials repeatedly overlook women’s needs and health. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.

Read more

A Bloody Business: American Vaccine Production at the Turn of the Twentieth Century

Editor’s Note: Patrick M. Walsh is a doctoral candidate in the Department of History at the University of Wisconsin–Madison. He studies the the cross-talk between bacteriology, immunology and endocrinology in the late-nineteenth and early-twentieth centuries.

Vaccines and Blood
“Preparation of an Antitoxin” at Parke-Davis Laboratories during the 1920s. Left: “Bleeding and siphoning—Collection of blood from the immunized animal in a large bottle containing oxalate.” Right: “Removal of antitoxic plasma by siphoning after the formed elements of the blood have been allowed to settle out.” Source: Parke-Davis and Company Biological Products catalog, c. 1930, Courtesy of AIHP Kremers Reference Files.

Blood is everywhere I look in the Kremers Reference Files (KRF) at the American Institute of the History of Pharmacy (AIHP). It’s in trade manuals published from the 1890s to the 1930s by Parke-Davis, Eli Lilly, and H. K. Mulford. It’s in advertisements from meatpacking-turned-drug companies, including Bovinine and the Cudahy Packing Company. It’s in dusty, century-old newspaper clippings that describe how tons of animal flesh were transported from slaughterhouse to factory line, ripe for experimentation and drug production.

I came to the KRF to start my dissertation work about the American vaccine industry at the turn of the twentieth century, but, instead, all I found was blood. Image after image of blood being suctioned out of stable-bound horses. Blood coursing through plastic tubes that look like fiberoptic cables. Blood being rapidly deposited into oversized receptacles, red foam climbing up the sides of the glass. Some of the images look almost staged—deliberately and self-consciously reenacting a scene from Mary Shelley’s Frankenstein, then just 80 years old.

Maybe I shouldn’t have been surprised. I knew before going into the KRF that the vaccine industry was fully launched in the 1890s with the diphtheria antitoxin vaccine, that this was a “serotherapy,” and that all serotherapies involve a process of blood harvesting. It is a vampiric practice by definition. Hundreds of horses stand at attention, and scientists buzz around them like angry mosquitoes, directing their syringes with precision into pulsing jugulars, delighting at the extraction of potent antitoxins that hurtle invisibly through equine vascular systems. Antitoxin-rich blood was as good as gold at the turn of the century, and it brought companies like Parke-Davis and H. K. Mulford material, social, and political capital.

Read more